AGN AGN アラガン

 AGNのチャート


 AGNの企業情報

symbol AGN
会社名 Allergan PLC (AGN アラガン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アラガン(Allergan plc)は特殊医薬品会社である。同社はブランド医薬品、医療美学、バイオシミラーおよび市販薬の開発、製造、販売および流通に従事する。同社は米国特殊療法、米国一般医学および国際の3つのセグメントを通じて事業を行う。米国特殊療法事業には、医療美学、医療皮膚科、眼科治療、神経科学および泌尿器科治療薬を含む米国内のブランド製品に関する販売が含まれる。米国一般医学事業には中枢神経系、胃腸管、女性健康、抗感染症および多様化ブランドを含む米国特化治療薬ビジネスユニットに該当しない米国内のブランド製品に関する販売が含まれる。国際セグメントには米国外で販売される製品に関する販売が含まれる。  アラガンはアイルランド医薬品企業。ジェネリック医薬品とブランド医薬品の製造・販売に従事。米国内で約250種類のジェネリック医薬品を扱い、ブランド医薬品には骨粗しょう症薬「アクトネル」や「アテルビア」、テストステロン補充薬「アンドロダ―ム」、プロゲステロン補充薬「クリノン」、造血剤「INFeD」、潰瘍性大腸炎「アサコ―ル」などがある。  Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.
本社所在地 Clonshaugh Business and Technology Park Coolock Dublin 07054 IRL
代表者氏名 Brenton L. Saunders
代表者役職名 Chairman of the Board President Chief Executive Officer
電話番号 +353 21-6523-5000
設立年月日 1983年
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 16900人
url www.allergan.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 7004.30000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 48715.04000
売上高 売上高(百万ドル) 15787.40000
企業価値(EV) 企業価値(EV)(百万ドル) 70605.44000
当期純利益 当期純利益(百万ドル) -5157.10000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Allergan plc revenues decreased 1% to $15.79B. Net loss applicable to common stockholders excluding extraordinary items decreased 24% to $5.16B. Revenues reflect US Medical Aesthetics segment decrease of 8% to $5.32B. Lower net loss reflects Asset sales and impairments net decrease of 27% to $2.86B (expense) In process research and development decrease of 45% to $804.6M (expense).

 AGNのテクニカル分析


 AGNのニュース

   AbbVie Inc. Completes Acquisition of Allergan plc  2020/05/08 20:20:00 PR Newswire
DUBLIN, May 8, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") announced…
   COVID-19 Impact and Recovery Analysis- Global Chemical Peel Market 2020-2024 | Evolving Opportunities with Allergan Plc and Bausch Health Companies Inc. | Technavio  2020/05/08 11:30:00 Business Wire
LONDON--(BUSINESS WIRE)-- #ChemicalPeelMarket--The chemical peel market is poised to grow by 62.78 mn during 2020-2024, according to Technavio
   The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Million  2020/05/07 13:00:00 PR Newswire
DUBLIN, May 7, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation's total…
   Is Aegon NV (AEG) Stock Undervalued Right Now?  2020/05/06 15:50:15 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
   Announcement relating to the outcome of the Court Sanction Hearing  2020/05/06 10:55:00 PR Newswire
DUBLIN, May 6, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") today…

 関連キーワード  (医薬品 米国株 AGN アラガン AGN )

 twitter  (公式ツイッターやCEOツイッターなど)